Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.

Background: Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK.

Methods: Data was retrospectively collected from 16 tertiary UK cancer centres.

A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer.

Aims: Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer. The study aim was to analyse demographics and outcomes of UK patients treated with fulvestrant monotherapy at nine representative centres.

Materials And Methods: Medical records of 459 patients with locally advanced or metastatic ER-positive, HER2-negative breast cancer treated with fulvestrant between August 2011 and November 2018 at nine UK centres were reviewed.

Family caregiver beliefs and barriers to effective pain management of cancer patients in home care settings.

Purpose: Pain is one of the most common symptoms in cancer patients, and its management is a significant goal in supportive care. Many barriers interfere with its effective control. Nowadays, with a shift in care from the hospital to the home, there is an increasing tendency to involve family caregivers in pain management.

Breaking bad news in cancer patients.

Objective: In a regional hospital, many patients are newly diagnosed with cancer. Breaking the bad news in these patients and their relatives is a tough task. Many doctors are not experienced in talking to patients about death or death-related diseases.

The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.

Background: The oxaliplatin (ΟΧΑ)-based regimens FOLFOX and XELOX can cause peripheral neuropathy. It is unknown if ΟΧΑ, alone or in combination regimens, affects the Autonomous Nervous System (ANS). Accordingly, we evaluated the impact of ΟΧΑ-based chemotherapy on the ANS.